Modelling mass drug administration strategies for reducing scabies burden in Monrovia, Liberia.
Liberia
agent-based modelling
mass drug administration
scabies
transmission
Journal
Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737
Informations de publication
Date de publication:
18 08 2023
18 08 2023
Historique:
medline:
26
9
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
epublish
Résumé
Scabies is a parasitic infestation with high global burden. Mass drug administrations (MDAs) are recommended for communities with a scabies prevalence of >10%. Quantitative analyses are needed to demonstrate the likely effectiveness of MDA recommendations. In this study, we developed an agent-based model of scabies transmission calibrated to demographic and epidemiological data from Monrovia. We used this model to compare the effectiveness of MDA scenarios for achieving scabies elimination and reducing scabies burden, as measured by time until recrudescence following delivery of an MDA and disability-adjusted-life-years (DALYs) averted. Our model showed that three rounds of MDA delivered at six-month intervals and reaching 80% of the population could reduce prevalence below 2% for three years following the final round, before recrudescence. When MDAs were followed by increased treatment uptake, prevalence was maintained below 2% indefinitely. Increasing the number of and coverage of MDA rounds increased the probability of achieving elimination and the number of DALYs averted. Our results suggest that acute reduction of scabies prevalence by MDA can support a transition to improved treatment access. This study demonstrates how modelling can be used to estimate the expected impact of MDAs by projecting future epidemiological dynamics and health gains under alternative scenarios.
Identifiants
pubmed: 37593956
doi: 10.1017/S0950268823001310
pii: S0950268823001310
pmc: PMC10548539
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e153Références
Health Serv Res. 2011 Dec;46(6pt2):2057-78
pubmed: 21517835
Lancet Reg Health West Pac. 2021 Feb 15;7:100102
pubmed: 34327421
PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005726
pubmed: 28671945
PLoS Negl Trop Dis. 2022 Feb 3;16(2):e0010147
pubmed: 35113888
Trop Dis Travel Med Vaccines. 2021 Jul 1;7(1):21
pubmed: 34193305
Bull World Health Organ. 2005 Jan;83(1):34-42
pubmed: 15682247
PLoS Negl Trop Dis. 2020 Dec 7;14(12):e0008943
pubmed: 33284821
PLoS Negl Trop Dis. 2021 Sep 2;15(9):e0009661
pubmed: 34473725
Clin Infect Dis. 2022 Sep 29;75(6):959-967
pubmed: 35088849
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
PLoS Negl Trop Dis. 2022 Jun 9;16(6):e0010456
pubmed: 35679325
PLoS Negl Trop Dis. 2015 Dec 01;9(12):e0004246
pubmed: 26624616
Lancet. 1991 Apr 27;337(8748):1016-8
pubmed: 1673175
Pediatr Infect Dis J. 1997 May;16(5):494-9
pubmed: 9154544
Clin Microbiol Infect. 2012 Apr;18(4):313-23
pubmed: 22429456
Postgrad Med J. 2004 Jul;80(945):382-7
pubmed: 15254301
Math Biosci. 2019 Mar;309:163-173
pubmed: 30149021
Lancet Infect Dis. 2015 Aug;15(8):960-7
pubmed: 26088526
Australas J Dermatol. 2000 Aug;41(3):139-43; quiz 144-5
pubmed: 10954983
PLoS Comput Biol. 2018 Mar 26;14(3):e1006046
pubmed: 29579037
Clin Infect Dis. 2020 Apr 10;70(8):1591-1595
pubmed: 31131410
Lancet. 2019 Jul 6;394(10192):81-92
pubmed: 31178154
PLoS One. 2011 Jan 25;6(1):e15990
pubmed: 21283575
PLoS Negl Trop Dis. 2018 Dec 27;12(12):e0006996
pubmed: 30589906
PLoS Negl Trop Dis. 2015 Oct 30;9(10):e0004151
pubmed: 26516764
N Engl J Med. 2019 Jul 11;381(2):186-187
pubmed: 31242358
PLoS One. 2016 Aug 31;11(8):e0161311
pubmed: 27580098
PLoS Negl Trop Dis. 2020 Jun 26;14(6):e0008423
pubmed: 32589632
Lancet Infect Dis. 2019 May;19(5):510-518
pubmed: 30956111
Epidemics. 2015 Dec;13:56-64
pubmed: 26616042
N Engl J Med. 2015 Dec 10;373(24):2305-13
pubmed: 26650152
Trop Med Infect Dis. 2018 Sep 05;3(3):
pubmed: 30274494